
To review zzso and clinical information on zzso an inhibitor of zzso zzso zzso tested as an zzso zzso 

zzso and review articles were identified by zzso search zzso zzso zzso from recent meetings were also used as source zzso 

zzso was reviewed with regard to its mechanisms, zzso and clinical results, zzso and zzso 

zzso is an inhibitor of several zzso and displays unique zzso zzso In addition to direct zzso zzso zzso also exhibited other features such as inducing zzso in many cancer cell lines, decreasing zzso D1 zzso and zzso zzso zzso zzso models showed significant zzso activity for zzso The regimen using 72-hour continuous infusion every 2 weeks has been most extensively applied in clinical trials, with a zzso infusion currently being explored to achieve higher peak zzso Several Phase I and II trials have been reported, with some evidence of zzso activity zzso Further Phase I and II trials using zzso as a single agent and in combination with standard zzso regimens and various tumor types are zzso 

zzso is the first zzso inhibitor to enter clinical zzso Several Phase I and Phase II clinical trials with different regimens zzso or zzso zzso have been zzso zzso clinical trials have been intriguing, but many questions remain: What is the best regimen zzso or zzso zzso Does optimal future development of this drug depend on the combination with other zzso What is the best combination of zzso with other zzso 

